

## Thermo Fisher expands hematology oncology NGS portfolio

19 July 2021 | News

### Immune repertoire assays offer high detection rates of malignant clones, empowering researchers to better assess blood cancers



Thermo Fisher Scientific has announced a new suite of [Ion Torrent OncoPrint immune repertoire assays](#) designed to detect potentially malignant clones of T-cells and B-cells, which play a key role in the immune response system.

Using proprietary Ion AmpliSeq technology, the new pan-clonality assays target multiple parts of the B- and T-cell immune receptors using a single reaction with ultra-high sensitivity, thereby increasing the probability of malignant clone detection and decreasing the time to results.

Detection of distinct receptor DNA sequences can inform diagnostic, prognostic and therapy development studies in the progression of lymphoid cancers including leukemias, lymphomas and diseases such as multiple myeloma.

Using next-generation sequencing (NGS) technology, detection sensitivity can be increased compared to traditional testing methods such as flow cytometry or qPCR.

Thermo Fisher's new suite of immune repertoire assays are available on the Ion GeneStudio S5 System and feature integrated analysis and data visualization tools that simplify the interpretation of results for laboratories and healthcare professionals.